Tolfedine 4% w/v Solution for Injection for dogs and cats

国家: 爱尔兰

语言: 英文

来源: HPRA (Health Products Regulatory Authority)

有效成分:

Tolfenamic acid

可用日期:

Vetoquinol Ireland Limited

ATC代码:

QM01AG02

INN（国际名称）:

Tolfenamic acid

剂量:

4 percent weight/volume

药物剂型:

Solution for injection

处方类型:

POM: Prescription Only Medicine as defined in relevant national legislation

治疗组:

Cats, Dogs

治疗领域:

tolfenamic acid

疗效迹象:

N.S.A.I.D.

授权状态:

Authorised

授权日期:

1993-08-12

产品特点

_ _
_[Version 8.1, 01/2017] _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Tolfedine 4% w/v Solution for Injection for dogs and cats
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE
Tolfenamic acid
40 mg
EXCIPIENTS
Benzyl alcohol
10.4 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Sterile solution for injection.
A clear colourless to slightly yellow sterile aqueous solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs, Cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
IN DOGS
: inflammatory and painful post-operative syndromes.
IN CATS
: adjuvant treatment of upper respiratory disease in association with
antimicrobial therapy.
4.3
CONTRAINDICATIONS
Tolfenamic acid is contraindicated in case of cardiac disease.
Do not use in animals with impaired hepatic function or acute renal
insufficiency.
Tolfenamic acid is contraindicated in case of ulceration or digestive
bleeding, in case of blood
dyscrasia or hypersensivitivy to tolfenamid acid.
Do not inject intramuscularly in cats.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
NSAIDS can cause inhibition of phagocytosis and hence in the treatment
of inflammatory conditions
associated with bacterial infections. Appropriate concurrent
antimicrobial therapy should be instigated.
The use of insulin-type needle/syringe is advisable particularly in
low-weight animals to ensure an
accurate dose.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Use in animals less than 6 weeks of age, or in aged animals, may
involve additional risk. If such a use
cannot be avoided, animals may require a reduced dosage and careful
clinical management is essential.
Reduced metabolism and excretion in these animals should be
considered.
Avoid use in any dehydrated, hypovolemic or hypotensive animal, as
there is a potential risk of
increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be
avoided.
It is preferable that the product